Saturday 17 October 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.10
0.21
−6.34%
Follow CLNN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 2 | 3 | 2 |
| 370.05% | 197.91% | 281.87% | 237.15% | ||
| (113.20%) | (115.13%) | (142.67%) | (174.99%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(284.42%) | (619.63%) | (280.19%) | (256.98%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 79.67 | |
Free Cash Flow per Share |
(1.81) | (1.89) | (1.55) | (1.29) | |
Free Cash Flow |
(18.63) | (18.59) | (18.06) | (15.95) | |
Capital Expenditures |
(0.01) | (0.04) | — | (0.04) | |
| Other line items | |||||
Cash ROIC |
(164.07%) | (1,633.30%) | (520.25%) | (497.60%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 3.68 | |
Accounts Payable Turnover |
0.00 | 0.07 | 0.00 | 0.10 | |
Inventory Turnover |
0.00 | 1.50 | 0.00 | 1.67 | |
Average Days of Payables |
0.00 | 4,121.27 | 0.00 | 4,297.22 | |
Days of Inventory on Hand |
0.00 | 170.95 | 0.00 | 139.23 | |
Tax Rate |
(0.64) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6,577.57% | 7,005.50% | 9,596.27% | 6,505.58% | |
Selling, General and Administrative Expense of Revenue |
4,833.18% | 4,614.50% | 6,208.96% | 3,996.45% | |
Share Based Compensation of Revenue |
3,185.98% | 3,191.00% | 4,288.81% | 2,751.27% | |
Interest Coverage |
(9.89) | (8.61) | (7.35) | (7.13) | |
Operating CF/Net income |
0.61 | 0.71 | 0.54 | 0.40 | |
Depreciation/Fixed assets |
0.24 | 0.25 | 0.26 | 0.27 | |
Capex/Depreciation |
(0.01) | (0.03) | 0.00 | (0.03) | |
Revenue per Share |
0.02 | 0.02 | 0.01 | 0.02 | |
Operating CF per Share |
(1.81) | (1.88) | (1.55) | (1.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.21 | 0.00 | 0.21 |
Columns are period end dates